Pharmaceuticals News

SAN CLEMENTE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners...

HIGH POINT, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for...

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced...

– Expands patient access to opioid-sparing pain control and advances 5x30 strategy –  BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry...

Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks,...

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing.

ORION OYJLEHDISTÖTIEDOTE05.10.2026 KLO 15.00 Ensimmäinen potilas on saanut hoitoa Orion Pharman Faasi 1/2 -tutkimuksessa ODM-216-molekyylillä, joka on yhtiön ensimmäinen kliiniseen kehitysvaiheeseen...

A new patent application covers Polyrizon’s proprietary mucoadhesive platform and its potential applications in nasal drug delivery. Raanana, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) --  Polyrizon...

Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to...

- In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12...